Indaptus Therapeutics, Inc.

INDP
$2.39 (+ $0.36 + 18.02%)
Last updated: 2026-06-10 20:02 UTC
INDP Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS45339J2042
CUSIP45339J204
Market Price2.39
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-29.03
Market Cap$4.6M
Book Value2.81
Price to Book0.945
Beta1.04
52w High47.6
52w Low1.65
Next Earnings DateN/A

Indaptus Therapeutics, Inc. trades under ticker INDP on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US45339J2042, CUSIP 45339J204.

About the Company
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Price History